Fixed 39th Annual General Meeting of the Company and Book Closure of Register of Members
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.5 pts more than Nifty Microcap 250 and 7.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
IOL Chemicals & Pharmaceuticals reported strong FY2026 results with standalone revenue from operations of Rs 2,319.06 crore, up 11.5% from Rs 2,079.21 crore in FY2025. Net profit after tax grew 36.4% to Rs 137.72 crore from Rs 101.00 crore, with EPS rising to Rs 4.69 from Rs 3.44. EBITDA margin expanded from 6.6% to 8.4%, reflecting improved operational efficiency. An exceptional item of Rs 11.21 crore was recorded due to labour code amendments requiring recognition of past service costs for employees. The company fixed its 39th AGM for 2nd September 2026 and announced capacity expansions: new Triacetin plant (6,000 MTPA, Rs 16.88 crore) and enhanced Pantoprazole capacity (276 MTPA from 240 MTPA, Rs 5.87 crore), both funded through internal accruals. Statutory auditors issued an Unmodified Opinion.
The company delivered robust profit growth with margin expansion, signalling operational efficiency gains. The new Triacetin plant diversifies the product portfolio into multi-industry applications, while Pantoprazole capacity increase addresses growing demand. The clean audit opinion and internally funded capex plans are positive for shareholders.